MedTrace Logo

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

NCT05600127 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-09-08

No results posted yet for this study

Summary

Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.

Conditions

Interventions

DRUG

Avelumab

3 cycles of avelumab (800mg, every 2 weeks)

Sponsors & Collaborators

Principal Investigators

  • J L Boormans, MD PhD · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-04-30
Completion
2026-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05600127 on ClinicalTrials.gov